Verseau Therapeutics is a biotech startup that operates in the field of cancer immunotherapies. The company's primary focus is on developing a new class of treatments that stimulate the conversion of certain types of cells, specifically M2 macrophages, into a different type, M1 macrophages. This process, known as macrophage repolarization, triggers a coordinated immune response to combat cancer. In simpler terms, Verseau is working on a way to make the body's own immune system more effective in fighting cancer.

The company's proprietary discovery engine, a unique tool that helps them identify and validate potential targets for treatment, has already identified over 20 targets for regulating cell biology. Their two main programs, which focus on PSGL-1 and VSIG4, are making significant progress towards clinical trials.

Verseau's clients are primarily in the healthcare sector, including hospitals, clinics, and other medical institutions, as well as individual patients suffering from cancer. The company operates in the biotech market, which is highly competitive and research-intensive.

Verseau's business model is based on research and development of innovative cancer treatments. The company invests heavily in research to discover and develop new therapies, which are then patented and sold to healthcare providers. The company makes money by selling these patented therapies and treatments.

Keywords: Biotech, Cancer Immunotherapies, Macrophage Repolarization, M2 Macrophages, M1 Macrophages, PSGL-1, VSIG4, Healthcare Sector, Research and Development, Patented Therapies.